GENTA INC. Neue trend zum letzten Mal ?
Seite 40 von 78 Neuester Beitrag: 10.02.12 22:13 | ||||
Eröffnet am: | 21.02.11 14:14 | von: brunneta | Anzahl Beiträge: | 2.948 |
Neuester Beitrag: | 10.02.12 22:13 | von: doschauher | Leser gesamt: | 166.217 |
Forum: | Hot-Stocks | Leser heute: | 36 | |
Bewertet mit: | ||||
Seite: < 1 | ... | 37 | 38 | 39 | | 41 | 42 | 43 | ... 78 > |
und das kann Nebenwirkungen nach sich ziehen.
Aber es gibt zum Glück die Pillenbox.
Klingt sicher bissl überheblich, weil ich das nochmal erwähne, aber bei dem Gesamtchart bin ich da schon bissl stolz drauf :)
Genta Initiates Tesetaxel Clinical Trial in Japan to Kickoff Comprehensive Development Program in East Asia
April 26, 2011
--Trial is First Global Step in Targeting Patients with Advanced Gastric Cancer
BERKELEY HEIGHTS, NJ – April 26, 2011 – Genta Incorporated (GNTA.OB) today announced that the Company has initiated a new clinical trial of tesetaxel in Japan as part of a comprehensive new initiative. Tesetaxel, the leading oral taxane in clinical development, will be evaluated over a limited dosing-range as a single agent in patients with advanced cancer. The new trial will be conducted at Kinki University in Osaka, which will enable the next generation of clinical studies in Japan.
Genta has indicated that gastric cancer is a key initial target for registration studies with tesetaxel. While gastric cancer is the fourth most common tumor type on a global basis, its incidence ranks either first or second in most East Asian countries, including Japan, Korea, Taiwan, and China.
“This study’s initiation reflects Genta’s extensive interactions with Japan’s leading investigators and with the Pharmaceuticals and Medical Devices Agency (PMDA), the drug regulatory authority in Japan”, said Dr. Loretta M. Itri, Genta’s President, Pharmaceutical Development, and Chief Medical Officer. “We anticipate conducting substantial additional work throughout Japan and East Asia as activity in the tesetaxel development program continues to accelerate.”
Item 8.01 Other Events.
On April 21, 2011, Genta Incorporated updated its formal guidance for release of results from its Phase 3, randomized, controlled trial of Genasense® (oblimersen sodium) Injection in patients with advanced melanoma, also known as the AGENDA trial. After completion of final data collection, transfer and locking of the database, and statistical analysis, the Company expects to release a “top-line” statement regarding the result for overall survival in May 2011. The data collection process for this double-blind trial has not yet been completed.
Die Meldung ist von heute!!!!
Hast du überhaupt schon einmal auf die HP von Genta geschaut???
Oder hast du jemals die Filings gelesen????
Gruß
Ernie0815
und die Studie in Asien noch nicht für den Kurs von Bedeutung sind.
Bei dem Kurs wird keiner reich ausser wer wirklich ganz unten reingeht mit reichlich k und oben raus...